Clesrovimab, When Present In The Nasal Compartment, Can Neutralize RSV In Vitro, Study Finds

Pulmonology Advisor (1/22, Goldberg) reports, “Clesrovimab, when present in the nasal compartment, can neutralize respiratory syncytial virus (RSV) in vitro, suggesting that infants could potentially receive passive immunization against RSV through the use of clesrovimab, according to study findings.” Researchers came to this conclusion after conducting “an analysis of 2 separate cohorts of human samples, PN001 (phase I adult human dose escalating study for clesrovimab to evaluate the safety, tolerability, and pharmacokinetics of clesrovimab) and PN005 (healthy adult human RSV challenge study designed to inform a model-based meta-analysis [MBMA] that correlated RSV neutralization titers to RSV viral loads).” The research was published in Biomedicine & Pharmacotherapy.